Efficacy and safety of SPA100 (fixed-dose combination of aliskiren/amlodipine) in patients with essential hypertensio
Phase 3
- Conditions
- Essential hypertension
- Registration Number
- JPRN-jRCT2080221310
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 936
Inclusion Criteria
Patients with essential hypertension (msDBP more than 95 mmHg and below 110 mmHg and msSBP more than 140 mmHg)
- Outpatients
Exclusion Criteria
- Severe hypertension (msDBP more than 110 mmHg and/or msSBP more than 180 mmHg)
- History of allergy or hypersensitivity to renin inhibitors, calcium channel blockers
- History or evidence of a secondary hypertension
Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method